myelodysplastic syndromes (MDS) is a $3.5b market and Syntara only need to contribute 700k, more importantly it go straight into Phase 2 later this year.
This is substantially more commercialized focus and less time consuming than the previous myelofibrosis trails.
Not sure how long it'll take before the market realize this.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
6.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $97.64M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| SNT (ASX) Chart |
Day chart unavailable